ArticleSurgery2026
Return to intended oncologic therapy after treatment for cholecystitis in cancer patients.
Article in Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundReturn to intended oncologic treatment is a patient-centric quality metric that has been associated with survival in multiple malignancies. Emergency general surgery conditions, such as cholecystitis, are frequent events that can disrupt treatment.
methodsOur institutional database was queried using International Classification of Diseases, Ninth and Tenth Revision codes for patients on active cancer therapy who developed cholecystitis between January 1, 2010 and December 31, 2020. The primary outcome was return to intended oncologic treatment ≤6 weeks, stratified by whether patients were treated with surgery, drainage procedure, or no procedural management.
resultsOf 129 patients, 52.7% (N = 68) returned to therapy within 6 weeks, whereas 22.5% (N = 29) had a >6-week delay and 24.8% (N = 32) never received additional cancer-directed therapy. Return to intended oncologic treatment ≤6 weeks was associated with lower Eastern Cooperative Oncology Group (ECOG) scores (ECOG 0-1 81.8% vs 52.5%, P = .023), and patients were more likely to have solid malignancies (57.4%) or multiple malignancy types (23.5%). Patients with hematologic malignancies (OR, 0.41; 95% confidence interval, 0.17-0.98; P = .044) and those who underwent drainage procedures (OR, 0.32; 95% confidence interval, 0.13-0.81; P = .016) were less likely to return to intended oncologic treatment ≤6 weeks. Only 3 patients who had a percutaneous cholecystotomy tube placed (8.9%) would later undergo cholecystectomy.
conclusionHalf of the patients who develop cholecystitis while on cancer treatment return to intended oncologic treatment ≤6 weeks, and one-quarter will never return to treatment. Patients with hematologic malignancies and those who have drainage procedures are less likely to return to intended oncologic treatment ≤6 weeks. There is a low rate of interval cholecystectomy after percutaneous cholecystotomy tube placement, and percutaneous cholecystotomy tube is unlikely to expedite a return to cancer-directed therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.